Latest ArticlesTo investigate the effect of miR-506-3p on the chemosensitivity of ovarian cancer (OC) cells and its mechanism.
MiR-506-3p and never in mitosis gene A-related kinase 6 (NEK6) were detected by quantitative reverse transcriptase-mediated polymerase chain reaction (qRT-PCR) in cisplatin (DDP) resistant OC cell lines (SKOV3/DDP, A2780/DDP, HeyA8/DDP) and their parent cell lines (SKOV3, A2780, HeyA8). Lipofectamine 2000 was used to transfect miR-506-3p overexpressed SKOV3/DDP cells and DDP sensitive SKOV3 cells, respectively. The survival rate and half inhibitory concentration (IC50) of SKOV3/DDP cells and sensitive SKOV3 cells in each transfection group were measured by tetrazolium salt colorimetry (MTT). TargetScan predicted potential target genes of miR-506-3p, verified by double luciferase experiment. Western blott (WB) was used to determine the expression level of NEK6 protein after transfection.
The expression of miR-506-3p was low and NEK6 was high in OC drug-resistant cell lines. Transfection with miR-506-3p mimic significantly reduced the survival rate and IC50 value of SKOV3/DDP cells and SKOV3 sensitive cells. The survival rate and IC50 value of sensitive SKOV3 cells were lower than that of SKOV3/DDP cells, and the IC50 value of DDP on SKOV3/DDP cells was 2.1 times higher than that of sensitive SKOV3 cells. Co-transfection of miR-506-3p mimic and LV-NEK6 reversed the effect of miR-506-3p mimic alone on chemosensitivity of SKOV3/DDP cells. NEK6 is a potential target gene of miR-506-3p. The results of WB showed that miR-506-3p negatively regulates NEK6 protein expression.
MiR-506-3p increase chemosensitivity of ovarian cancer resistant cells by targeting inhibition of NEK6 expression.
To investigate the renal protective effects of L-amlodipine besylate on chronic kidney disease (CKD) spontaneously hypertensive rats (SHRs) and its mechanism.
A total of 40 male SHRs were randomly divided into sham operation group, model control group, routine dose group of L-amlodipine besylate (group A, 2.5 mg/kg one day) and high dose group (group B, 5 mg/kg one day), with 10 SHRs in each group. Except for sham operation group, CKD model was established on SHRs. SHRs in each group were given standard feeding and corresponding gavage treatment, and tail artery manometry was performed every 2 weeks. The 24-hour urinary protein, renal function indexes [serum creatinine (SCR), blood urea nitrogen (BUN)], serum inflammatory indexes [high sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) and tumor necrosis factor-α(TNF-α)] and oxidative stress indexes [malonaldehyde (MDA), superoxide dismutase (SOD)] were measured. The renal pathological changes of rats in each group were observed by hematoxylin eosin staining, Masson staining and periodic acid Schiffstain.
After 6 weeks of administration, the systolic and diastolic blood pressure in groups A and B were lower than those in the model control group, and group B was better than group A (P<0.05). The 24-hour urinary protein, Scr and BUN in the model control group were higher than those in the sham operation group (P<0.05), those in groups A and B were lower than those in the model control group, and those in group B were lower than those in group A (P<0.05). Compared with the sham operation group, the serum hs-CRP, IL-6, TNF-α and the level of MDA in the model control group increased significantly, and the level of SOD decreased (P<0.05), group A and group B were both better than the model control group, and group B was better than group A (P<0.05). No obvious abnormality was found in the renal pathological structure of the sham operation group. The renal pathological structure changes and damage in group B were lighter than those in group A, and those in group A were lighter than those in the model control group.
L-Amlodipine besylate can reduce blood pressure, reduce renal pathological changes, delay the deterioration of renal function and stabilize renal function in SHRs with CKD. The mechanism may be to protect the kidney and delay the progress of CKD by improving the state of micro inflammation and oxidative stress.
To compare the effects of traditional analgesia and multimodal analgesia (MMA) after lumbar disc herniation.
A total of 64 patients who required lumbar disc herniation in the department of orthopedics, the Second Affiliated Hospital of Xi'an Jiaotong University from November 2016 to October 2018 were randomly divided into the control group and observation group, with 32 cases in each group. The control group was treated with routine analgesic drugs at any time according to the pain of patients. The observation group was given MMA. Patients were given preemptive analgesia before operation, with intravenous injection of flurbiprofen axetil. Then the observation group was given conventional indwelling of one-time patient-controlled intravenous analgesia pump (butorphanol+sufentanil+tropisetron). The patients were given ward analgesia scheme after operation, with intravenous injection of flurbiprofen axetil. Visual analogue scale (VAS) was used to compare the VAS scores at 4 h, 8 h, 24 h, and 48 h at rest and activity.
In terms of VAS score, there was significant difference in time and interaction between the two groups (P<0.01). The observation group was significantly better than the control group, the difference was statistically significant (P<0.05), and the curative effect gradually increased with time. VAS scores of the two groups at 24 h and 48 h after operation were lower than those at 4 h after operation, and the difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (6.25% vs 25.00%), and the difference was statistically significant (P<0.05).
Compared with the traditional analgesia mode, MMA has better analgesic effect and safety in the clinical application of postoperative lumbar disc herniation. It can effectively reduce the early postoperative pain response and is conducive to the early postoperative functional rehabilitation.
To investigate the effects of cinobufotalin capsule combined with interferon alpha on postoperative immune function and long-term prognosis in patients with primary small hepatocellular carcinoma.
From January 2014 to January 2015, 106 patients with primary small hepatocellular carcinoma who underwent surgical resection in our hospital were selected and randomly divided into observation group and control group, with 53 cases in each group. The control group were treated with interferon-α, the observation group was treated with cinobufotalin capsule combined with interferon-α for 18 months. The differences of immune function and long-term prognosis were compared between the two groups.
K-M survival curve analysis showed that the survival time of patients in the observation group was significantly higher than that in the control group (P<0.05). There were no significant differences in alpha fetoprotein (AFP), immunoglobulin (Ig) A, IgM, IgG, complement C3 and C4 between the two groups before treatment (P>0.05). After treatment, compared with the control group, AFP in the observation group decreased (21.891.56)vs (23.781.88), (P<0.05); IgA increased (1.650.05) vs (0.980.02) g/L, (P<0.01); IgM increased (1.03±0.11) vs (0.91±0.13)g/L, (P<0.01); IgG increased (12.44±1.08) vs (7.18±1.36)g/L, (P<0.01); C3 increased (1.25±0.0) vs (0.98±0.02)g/L, (P<0.01); C4 increased (0.23±0.01) vs (0.18±0.03)g/L, (P<0.01).
Cinobufotalin capsule combined with interferon-α has a significant effect on the improvement of postoperative immune function and long-term prognosis in patients with small hepatocellular carcinoma, which has a certain clinical value.
To observe the effects of long-term intervention of resistant starch (RS) on saccharometabolism and lipid metabolism in patients with type 2 diabetes mellitus (T2DM).
A total of 60 patients with T2DM diagnosed in the inpatient department of endocrinology of Shuguang hospital affiliated to Shanghai university of traditional Chinese medicine, from June 2015 to June 2016, were randomly divided into observation group and control group, with 30 cases in each group. The observation group was given RS biscuits and control group was given daily diet for 12 weeks, followed up once every 4 weeks. The indexes of saccharometabolism [fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hBG), glycosylated hemoglobin A1c (HbA1c)], lipid metabolism [total cholesterol (TC), triacylglycerol (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C)], fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR) were compared and analyzed before and after intervention.
Before intervention, there was significant difference in TC and HDL-C between the two groups (P<0.05). After the intervention, FBG and HbA1c in the control group were lower than those before the intervention (P<0.05). In the observation group, FBG, 2hBG and HbA1c were all decreased (P<0.05), TG, TC and LDL-C were all decreased (P<0.05). At the 8th week of intervention, FBG and 2hBG in the two groups were significantly lower than that at the 4th week of intervention (P<0.05). Compared with the control group, the difference of TC and LDL-C in the observation group was significantly higher than that in the control group (P<0.05).
Long-term administration of RS can improve the disorder of saccharometabolism and lipid metabolism in patients with T2DM, which can be used as one of the nutritional treatment schemes of T2DM.
To explore the effects of liraglutide on the levels of serum fibroblast growth factor 21 (FGF21) and protein tyrosine phosphatase 1B (PTP1B) in patients with obesity type 2 diabetes mellitus (T2DM).
A total of 80 obesity T2DM patients who were treated in the inpatient department of endocrinology department of first central hospital of Baoding city, Hebei province from March 2019 to January 2020 were randomly divided into control group and observation group, with 40 cases in each group. The control group was treated with oral drugs, and the observation group was treated with liraglutide on the basis of the control group. The course of treatment of both groups was 3 months. The body mass index (BMI), waist circumference, hip circumference, fasting blood glucose (FBG), 2-hour postprandial blood glucose (2hPG), glycosylated hemoglobin A1c (HbA1c), serum FGF21 and PTP1B concentrations were compared between the two groups before and after treatment. The correlation between serum FGF21 and PTP1B were analyzed.
Before treatment, there was no significant difference in BMI, waist circumference, hip circumference, FBG, 2hPBG, HbA1c, FGF21 and PTP1B between the two groups (P>0.05). After treatment, the levels of the above indexes in the two groups decreased, and the levels in the observation group were lower than those in the control group, the differences were statistically significant (P<0.05). There was a positive correlation between serum FGF21 and PTP1B (r=0.45, P<0.05).
Liraglutide can significantly reduce the fat content, improve the blood glucose level, decrease the levels of serum FGF21 and PTP1B in patients with obesity T2DM, and improve therapeutic effect.
To explore the clinical efficacy of thalidomide combined with glucocorticoid in the treatment of refractory nephrotic syndrome.
Totally 120 patients with refractory nephrotic syndrome were randomly divided into control group (CG) and observation group (OG), according to random number table method, 60 cases in each group. CG were treated with glucocorticoid. OG were given thalidomide combined with glucocorticoid. The total remission rate, renal function indexes (serum creatinine, blood urea nitrogen and 24-hour urinary protein), serum albumin, clinical efficacy, incidence adverse reactions and quality of life scores were observed and compared between the two groups after treatment.
There was no statistical significance in the two groups before treatment (P>0.05). After treatment, the total remission rate of OG was higher than that of CG (95.00% vs 78.33%, P<0.05). Compared with CG, serum creatinine, blood urea nitrogen and 24 h urinary protein of OG were decreased, while the serum albumin was increased (P<0.05). However, the incidence of adverse reactions of OG was higher than that of CG (33.33% vs 25.00%, P<0.05). The quality of life scores of OG was significantly higher than that of CG [(334.33±6.23) vs (291.11±6.94), P<0.05].
Thalidomide combined with glucocorticoid can effectively treat refractory nephrotic syndrome, improve the renal function of patients and quality of their life. However, the increased incidence of adverse reactions during and after treatment should be paid close attention.
To compare the clinical effect of piperacillin/tazobactam sodium and cefoperazone/sulbactam in the treatment of the non-severe elderly with hospital-acquired pneumonia (HAP).
A total of 196 patients with HAP in Beijing First Hospital of Integrated Chinese and Western Medicine were enrolled between August 2019 and October 2021. They were randomly divided into group A and group B, 98 cases in each group. Group A was treated with piperacillin/tazobactam sodium, while group B was treated with cefoperazone/sulbactam. The clinical curative effect was compared between the two groups.
There was no significant difference in response rate of clinical treatment or bacterial clearance rate between the two groups (80.61% vs 77.55%; 89.57% vs 88.03%) (P>0.05). There was no significant difference in disappearance time of cough, antipyretic time, disappearance time of lung rales and fade time of lung shadow between the two groups (P>0.05). There was no significant difference in levels of interleukin 6, interleukin 8, tumor necrosis factor α and high sensitivity C-reactive protein between the two groups after treatment (P>0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The treatment cost was relatively lower in group A. Compared with group A, there was one unit increase of total response rate while there was a increase of 105.16 yuan treatment cost in group B.
There is no difference in the clinical curative effect of piperacillin/tazobactam sodium and cefoperazone/sulbactam on the elderly with non-severe HAP. However, cost-effectiveness ratio of piperacillin/tazobactam sodium is lower.
To explore the clinical effect of atomization inhalation of self-made traditional Chinese medicine and acupuncture in the prevention and treatment of pharynx and larynx complications in patients after endotracheal intubation.
The total of 150 patients with parotid tumor who underwent endotracheal intubation under general anesthesia from May 2018 to May 2020 were selected. According to the simple random grouping method, the patients were divided into three groups: budesonide group, self-made traditional Chinese medicine group, self-made traditional Chinese medicine+acupuncture treatment group, each group 50 cases. The number of cough cases, the score of hoarseness and the Bergman comfort scale (BCS) of pharyngeal pain were compared among the three groups.
The time of cough disappearance in half patients in the self-made traditional Chinese medicine+acupuncture group was shorter than that in self-made traditional Chinese medicine group, which is shorter than budesonide group (P<0.05). At D3, the hoarseness score in the self-made traditional Chinese medicine+acupuncture group was significantly lower than that in the budesonide group and the self-made traditional Chinese medicine group (P<0.05); while D5 after operation, the hoarseness score of self-made traditional Chinese medicine+acupuncture group and the self-made traditional Chinese medicine group were significantly lower than that of the budesonide group (P<0.01). At D3, D5 and D7 after operation, the BCS scores in budesonide group were lower than those in self-made traditional Chinese medicine+acupuncture group and self-made traditional Chinese medicine group (P<0.05), the pharyngeal pain was serious in budesonide group.
The atomization inhalation and acupuncture treatment of self-made traditional Chinese medicine can effectively improve the symptoms of cough, hoarseness and pharyngeal pain sore of patients after endotracheal intubation, and shorten the rehabilitation time of pharynx and larynx complications.
To observe the clinical effect of Wubei decoction TaZi therapy combined with dexamethasone ointment on chronic eczema patients with blood deficiency and wind dryness types.
The 108 patients with chronic eczema syndrome of blood deficiency and wind dryness types who met the inclusion criteria permit as the research object, were randomly divided into traditional Chinese medicine group (treated with matrix cream combined with Wubei decoction), western medicine group (treated with clodixone cream combined with placebo), Chinese and western medicine group (treated with Wubei decoction and clodixone cream), with 36 patients in each group, once a day, 2 weeks for a course of treatment, the total course of treatment 8 weeks. Scoring atopic dermatitis index (SCORAD) was used to score before and at the secnd, fourth, sixth and eighth week after treatment. The symptom score and dermatology life quality index (DLQI) score of each course of treatment were observed and recorded. To observe the clinical efficacy and safety of traditional Chinese medicine and integrated traditional Chinese and western medicine in treating chronic eczema.
After 8 weeks of treatment, the total effective rate of Chinese and western medicine group (97.22%) was better than that of traditional Chinese medicine group (86.11%) and western medicine group (83.33%), the difference was statistically significant (P<0.05). However, the curative effect of traditional Chinese medicine group was the same as that of western medicine group (P>0.05). In each course of treatment, the SCORAD and DLQI scores of Chinese and western medicine group were better than those of traditional Chinese medicine group and western medicine group, and the differences were statistically significant (P<0.05).
Wubei decoction TaZi therapy combined with dexamethasone ointment in the treatment of chronic eczema with blood deficiency and wind dryness types has better overall efficacy and onset speed than single drug treatment, and has less adverse reactions and safety in the treatment process.